Allergy Therapeutics plc (LON:AGY – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 6.60 ($0.08) and last traded at GBX 6.30 ($0.08), with a volume of 370347 shares traded. The stock had previously closed at GBX 6.40 ($0.08).
Allergy Therapeutics Price Performance
The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The company has a market capitalization of £304.71 million, a price-to-earnings ratio of -106.47, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a 50-day moving average price of GBX 5.46 and a 200-day moving average price of GBX 5.05.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Stories
- Five stocks we like better than Allergy Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- CD Calculator: Certificate of Deposit Calculator
- 2 Drone Stocks Surging from Increased Media Attention
- What is Forex and How Does it Work?
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
